Comparative assessment of the anxiolytic-like activities of honokiol and derivatives.
Honokiol has previously been shown to be an effective anxiolytic-like agent in mice when administered for 7 days at 0.2 mg/kg/day prior to evaluation in an elevated plus-maze, while 20 mg/kg is required for efficacy as a single oral dose. The aim of this study was to find analogs of honokiol that are more effective for acute administration. Among the eight analogs evaluated, one partially reduced derivative of honokiol [3'-(2-propenyl)-5-propyl-(1,1'-biphenyl)-2,4'-diol] exhibited significant anxiolytic-like activity at 0.04 mg/kg. Following oral administration of 1 mg/kg of this analog, anxiolytic-like activity was clearly evident at 1 h, peaked at 3 h, and remained significant for longer than 4 h after treatment. Combined administration of the derivative with diazepam led to enhanced anxiolytic-like efficacy. Moreover, as with diazepam, the anxiolytic-like effect of the analog was reduced by flumazenil. In contrast, bicuculline, a GABA(A) antagonist, had no effect on the activity of the derivative. Taken together, these results suggest that this analog of honokiol acts at the benzodiazepine recognition site of the GABA(A)-benzodiazepine receptor complex.
Kuribara
H
H
Department of Neuropsychopharmacology (Tsumura), Gunma University School of Medicine, 3-39-22 Showa-machi, Gunma 371-8511, Maebashi, Japan.
Kishi
E
E
Kimura
M
M
Weintraub
S T
ST
Maruyama
Y
Y
D000818:Animals; D014151:Anti-Anxiety Agents / Q000737:chemistry / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D001713:Biphenyl Compounds / Q000737:chemistry / Q000627:therapeutic use*; D003975:Diazepam / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D017705:Lignans; D008297:Male; D051379:Mice; D000498:Allyl Compounds; D010636:Phenols
D014151:Anti-Anxiety Agents; D001713:Biphenyl Compounds; D003975:Diazepam; D017705:Lignans; C005499:honokiol; D000498:Allyl Compounds; D010636:Phenols